Please assess the completion status of the following clinical trial:

Trial Title: Bosentan Use in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥ 18 years of age with a body weight of ≥ 40 kg;~* For female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using intrauterine devices (IUDs);~* Patients diagnosed Type 2 diabetes with overt nephropathy (urinary albumin excretion ≥ 300mg/24h);~* Patients on current treatment with angiotensin II receptor blockers for ≥ 3 months;~* Patients stable for at least 3 months prior to screening (no change in medications for diabetic nephropathy);~* Provide written informed consent;~Exclusion Criteria:~* Patients with a history of pulmonary chronic obstructive disease, cardiac failure or coronary artery disease;~* Patients with documented cancers, acute infections or chronic inflammatory diseases;~* Patients who are pregnant or breast-feeding;~* Patients with known hepatic disorders or AST and ∕or ALT upper than normal limit;~* Patients with hemoglobin or hematocrit that is ≥ 30% below the normal range (patients with secondary polycythemia are permitted);~* Patients with systolic blood pressure \< 110mm Hg;~* Patients with plasmatic albumin level \< 30g/L;~* Patients with a documented creatinine clearance ≤ 60ml/min;~* Patients on anticoagulants or anti-inflammatory drugs, including cyclooxygenase inhibitors, AINS, prednisone and immunosuppressive drugs, platelet aggregation inhibitors, except low dose aspirin, ACE inhibitors, antidiabetic agents (rosiglitazone, pioglitazone) and antioxidants (vitamin E)(except statins or low-dose aspirin ≤ 80mg/day);~* Patients on treatment or planned treatment with another investigational drug;~* Patients who are receiving an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor, or with a prostanoid (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion;~* Patients who are receiving calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) at inclusion or are expected to receive any of these drugs during the study;~* Patients with a known hypersensitivity to bosentan or any of the excipients;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
- 2 (Type: PLACEBO_COMPARATOR): placebo given bid same as experimental arm;

Based on this trial design, predict the completion outcome and termination type (if applicable).